PALM BEACH, Florida,
November 16, 2016 /PRNewswire/ --
Increased funding due to overall market momentum is serving to
aid biotech and pharma companies within medicinal cannabis sector
to delve deeper into the research and development of cannabinoid
prodrug pharmaceutical solutions. Biotech companies in the
sector to watch include: Vitality Biopharma, Inc. (OTCQB:
VBIO), GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba
Pharmaceuticals, Inc. (NASDAQ: ZYNE), INSYS Therapeutics, Inc.
(NASDAQ: INSY) and NEMUS Bioscience, Inc. (OTCQB: NMUS).
Vitality Biopharma, Inc. (OTCQB: VBIO), a corporation
dedicated to the development of cannabinoid prodrug
pharmaceuticals, and to unlocking the power of cannabinoids for the
treatment of serious neurological and inflammatory disorders, today
announced that it is advancing its cannabosides pharmaceuticals for
treatment of narcotic bowel syndrome, a severe form of
opiate-induced abdominal pain.
Read the full Vitality Biopharma (VBIO) Press Release at
http://marketnewsupdates.com/news/vbio.html
Every day more than 650,000 opioid prescriptions are dispensed
by US pharmacies, resulting in over 200 million opioid
prescriptions dispensed annually. Studies have reported that
up to 81% of patients treated with opiates have functional bowel
disorders, but these common symptoms may lead to underdiagnosis of
opiate-induced severe abdominal pain. More than half (58%) of
opiate users have reported chronic abdominal pain in
independently-conducted clinical studies, and narcotic bowel
syndrome is the most severe form of this disorder, where abdominal
pain paradoxically increases despite continued administration of
narcotics to treat the pain. When undiagnosed, patients or
physicians continue to escalate dosages, which temporarily relieves
pain, but leads to addiction and also worsens the abdominal pain -
a vicious cycle. Narcotic bowel syndrome has dire
consequences for opiate users, as their quality-of-life has been
reported to be worse than patients with quadriplegia.
The clinical use of cannabinoids for resolving pain and
inflammation is well established, including in large (n=313)
independently-conducted clinical studies of inflammatory bowel
disease, where 84% of patients reported an improvement in abdominal
pain. Vitality's proprietary cannabosides enable the selective
delivery of cannabinoids to the intestinal tract, enabling large
concentrations of THC and CBD (Δ9-tetrahydrocannabinol and
cannabidiol, respectively) to be delivered without any resulting
psychoactivity.
In other sector related performances in yesterday's market
and recent developments of note:
GW Pharmaceuticals plc (NASDAQ: GWPH) close up
slightly on Tuesday on just over 1/2 Million shares
traded by the market close. GW Pharmaceuticals, a
biopharmaceutical company, together with its subsidiaries, engages
in discovering, developing, and commercializing cannabinoid
prescription medicines
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a
clinical-stage specialty pharmaceutical company dedicated to the
development of innovative transdermal synthetic cannabinoid
treatments, earlier this month announced the enrollment of the
first patients into the STAR 2 (Synthetic Transdermal Cannabidiol
for the Treatment of Epilepsy) clinical trial, an open-label
extension trial which allows patients who have completed the
STAR 1 clinical trial to receive treatment with ZYN002 CBD gel for
up to 52 weeks.
INSYS Therapeutics, Inc. (NASDAQ: INSY) closed down
slightly on Tuesday at $14.10 on just over 1/2 Million shares traded by
the market close. Insys Therapeutics, a specialty
pharmaceutical company, develops and commercializes supportive care
products. The company markets Subsys, a sublingual fentanyl spray
for breakthrough cancer pain in opioid-tolerant cancer patients in
the United States.
NEMUS Bioscience, Inc. (OTCQB: NMUS) announced yesterday
that significant data concerning the IOP lowering effect of NB1111
and duration of action will be presented at the 2016 AAPS National
Meeting being held in Denver,
Colorado on Today, November 16, 2016, at 8:30 a.m.
(MST) by the company's research and commercialization partner,
the University of Mississippi. The abstract, "Effect of
single versus multiple day regimen of Δ9 -THC-valine-hemisuccinate
(THCVHS) on the intra-ocular pressure (IOP) lowering activity in
normotensive rabbits" (abstract # 30W0830), reports data comparing
the Nemus prodrug of tetrahydrocannabinol (THCVHS) also known as
NB1111, to established glaucoma therapies of Pilocarpine and
Timolol, as well as standard Δ9 -THC in both emulsion and solid
lipid nanoparticle (SLN) eye drops
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party
publisher and news dissemination service provider, which
disseminates electronic information through multiple online media
channels. MNU is NOT affiliated in any manner with any
company mentioned herein. MNU and its affiliated companies
are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any
security. MNU's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to
be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly
urged to perform research and due diligence on their own and
consult a licensed financial professional before considering any
level of investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. MNU is not liable
for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. For current
services performed MNU has been compensated one thousand
nine hundred dollars for news
coverage of the current press release issued by Vitality Biopharma,
Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF
ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and MNU undertakes no
obligation to update such statements.
Contact Information:
Media Contact
email: info@marketnewsupdates.com - +1(561)325-8757
SOURCE MarketNewsUpdates.com